News

Pharming: US approval in sight
Enlarge image

RegulatoryNetherlandsSwedenUK

Pharming: US approval in sight

09.11.2012 - Dutch Pharming and its US-partner Santaris Inc. have reported positive Phase III results for Ruconest, their treatment of hereditary angioedema.

The development of Pharming's C1 inhibitor Rhucin, also called Ruconest outside Europe, seemed to be a never ending story. But after the Dutch company and its US-partner Santaris Inc. reported positive top-line data for the protein to treat hereditary angioedema, the story could come to a happy ending. 

Rhucin met the primary endpoint of reducing median time to beginning of symptom relief vs. placebo in the Phase III Study 1310 trial to treat acute attacks of hereditary angioedema (HAE). The positive data trigger a US$10m milestone payment to Pharming from Santarus, which has exclusive commercialisation rights to Rhucin in North America. "We are very pleased with these pivotal study results and look forward to working with our colleagues at Santarus to prepare and submit the Biologics License Application (BLA) for Ruconest to the FDA in the first half of 2013," said Bruno Giannetti, COO of Pharming.  "We anticipate that additional data from this Phase III study will be presented at an appropriate medical meeting in 2013." Last year, FDA refused a similar application. Pharming subsequently amended the protocol to address issues raised by FDA. The recombinant human complement 1 (C1) esterase inhibitor is approved as Rhucin in the EU to treat acute attacks of HAE and is co-marketed with Swedish Orphan Biovitrum (SOBI). Originally, Pharming had begun the first Phase III for Rhucin in April 2004.

Rhucin has exactly the same amino acid sequence as endogenous human C1 inhibitor protein. It is the second recombinant protein produced in transgenic animals to get to market in Europe, following the approval of ATryn, a recombinant antithrombin, extracted from transgenic goat milk, in 2006. In Europe, there is significant competition in the HAE space. Aside from a C1 inhibitor protein derived from human plasma, the main competition for Rhucin on the continent is Shire’s approved Firazyr, a bradykinin B2 receptor antagonist originally developed by German Jerini AG, which delivered sales of about US$10 million in 2010. Firazyr was the first new treatment for HAE in Europe in 30 years.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/pharming-us-approval-in-sight.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTECH PHARMACON (N)16.80 NOK17.07%
  • ALMIRALL (E)17.26 EUR4.61%
  • EUROFINS SCIENTIFIC (F)301.96 EUR4.16%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • DBV TECHNOLOGIES (F)67.75 EUR-7.57%
  • CO.DON (D)2.50 EUR-7.41%

TOP

  • KARO BIO (S)39.30 SEK2419.2%
  • BIOTECH PHARMACON (N)16.80 NOK78.2%
  • TRANSGENE (F)4.92 EUR75.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-42.7%
  • THROMBOGENICS (B)2.86 EUR-42.3%

TOP

  • KARO BIO (S)39.30 SEK4417.2%
  • ADOCIA (F)82.29 EUR370.5%
  • VERONA PHARMA (UK)5.00 GBP316.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-80.0%
  • BIOTEST (D)20.00 EUR-77.0%

No liability assumed, Date: 02.09.2015